



an Open Access Journal by MDPI

Therapeutic Agents for the Treatment of Tumors in the CNS

Guest Editors:

Dr. Gautham Gampa

1. Department of Pharmaceutics,
University of Minnesota Twin
Cities, MN, USA

2. Genentech Inc., San Francisco,
CA, USA

Dr. Sani H. Kizilbash

Mayo Clinic, Rochester, MN,
United States

Dr. Shannon P. Fortin Ensign

Mayo Clinic, Phoenix, AZ, USA

Deadline for manuscript
submissions:

closed (25 May 2025)

Message from the Guest Editors

This Special Issue aims to create a platform for the exchange of ideas and findings related to treatments for tumors in the central nervous system (CNS). The current shortage of disease-modifying treatments for patients with both primary and metastatic brain tumors represents one of the most significant unmet needs of our time. Our ability to effectively tap into otherwise-promising anti-cancer therapies is challenged by the blood–brain barrier, which severely restricts the entry of systemic/orally delivered therapeutic agents into the brain. We seek innovative thoughts, research, and approaches to tackling critical questions relevant to the treatment of debilitating brain tumors. This Special Issue aims to highlight the latest advances in treatments with transformative potential in neuro-oncology from experts in relevant fields such as pharmaceutical sciences, neuroscience, pharmacology, medical oncology, drug delivery, and clinical neurosurgery. Along with original research articles, we encourage authors to submit comprehensive up-to-date reviews that detail the current status of these treatments and that provide perspectives or future directions.



mdpi.com/si/163167

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e
Bioquímica (DQB) e Centro de
Química Estrutural (CQE),
Institute of Molecular Sciences,
Faculdade de Ciências,
Universidade de Lisboa, Lisboa,
Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](https://twitter.com/Pharmaceut_MDPI)